Evidence map›Paper›PMID 39780203›Full record

ArticleJournal of nanobiotechnology2025

Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis.

Xueli Zhao, Yuze Qin, Bowen Li, Yue Wang, Jiao Liu, Bo Wang, Jia Zhao, Jiaqi Yin, Lanlan Zhang, Jing Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xueli ZhaoDepartment of Biochemistry and Molecular Biology, Shaanxi Provincial Key Laboratory of Clinical Genetics, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.
Yuze QinDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Bowen LiDepartment of Biochemistry and Molecular Biology, Shaanxi Provincial Key Laboratory of Clinical Genetics, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China.
Yue WangDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Jiao LiuDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Bo WangDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Jia ZhaoDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Jiaqi YinDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Lanlan ZhangDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Jing LiDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Junzhe HuangDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Kun ChenDepartment of Anatomy, Histology and Embryology and K.K. Leung Brain Research Centre, School of Basic Medicine, Fourth Military Medical University, Xi'an, 710032, China. chenkun@fmmu.edu.cn.
Liwen LiuDepartment of Ultrasound, Xijing Hypertrophic Cardiomyopathy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China. liuliwen@fmmu.edu.cn.
Yuanming WuDepartment of Laboratory, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710032, China. wuym@fmmu.edu.cn.

Funding

National Natural Science Foundation of China 82001831, 82271893, 82071932Xijing Hospital Medical Personnel Training Propel Project XJZT24CY04, XJZT24LY01
6 · The paper itself

Abstract

backgroundCardiac fibrosis plays a critical role in the progression of various forms of heart disease, significantly increasing the risk of sudden cardiac death. However, currently, there are no therapeutic strategies available to prevent the onset of cardiac fibrosis. METHODS AND

resultsHere, biomimetic ATP-responsive nanozymes based on genetically engineered cell membranes are adapted to specifically recognize activated cardiac fibroblasts (CFs) for the treatment of cardiac fibrosis. By fusing the anti-FAP CAR genetically engineered cell membrane to zeolitic imidazole frameworks-90 (zif-90) cores loaded with antioxidant nanozymes CeO

conclusionsThese findings demonstrate that the combination of CeO

Indexed as

Adenosine TriphosphateCeriumFibrosisAnimalsBiomimetic MaterialsBiomimeticsConnective Tissue Growth FactorFibroblastsGenetic EngineeringHumansMaleMiceMyocardiumMyofibroblastsNanoparticlesRatsAdenosine Triphosphateceric oxideCeriumConnective Tissue Growth FactorRNA, Small InterferingATP-responsiveCardiac fibrosisGenetically engineeredNanozymeZeolitic imidazole frameworks-90

Identifiers

PMID39780203
PMCPMC11715444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.